CSIMarket Company Name, Ticker, Suppliers, else..
 
In8bio Inc   (NASDAQ: INAB)
 
Price: $1.0500 $-0.06 -5.405%
Day's High: $1.0901999473571777 Week Perf: -2.78 %
Day's Low: $ 1.04 30 Day Perf: -4.55 %
Volume (M): 36,529 52 Wk High: $ 2.73
Volume (M$): $ 0 52 Wk Avg: $1.67
Open: $1.09 52 Wk Low: $0.88



 Market Capitalization (Millions $) 20
 Shares Outstanding (Millions) 19
 Employees 17
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -19
 Cash Flow (TTM) (Millions $) 9
 Capital Exp. (TTM) (Millions $) 0

Business Description


In8bio Inc is a biotechnology company that specializes in the development of innovative and targeted cell therapies for the treatment of cancer and other diseases. The company focuses on utilizing its proprietary technologies and expertise to engineer T cells, which are important immune cells, to recognize and kill specific cancer cells. In8bio's approach aims to improve the effectiveness and safety of cell therapies, potentially offering better treatment options for patients. The company is dedicated to advancing the field of cell therapy and bringing novel therapies to market to address unmet medical needs.


   Company Address: 350 5th Avenue New York 10118 NY
   Company Phone Number: 600-6438   Stock Exchange / Ticker: NASDAQ INAB


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -4.35%    
EXEL   -3.64%    
GILD   -1.88%    
MRNA        1.96% 
NVAX   -9.42%    
STRO   -18.82%    
• View Complete Report
   



Clinical Study

Breaking New Ground in Cancer Therapy IN8bios INB-100 Trial Welcomes The Ohio State University,

Published Wed, Oct 29 2025 12:45 PM UTC

Expanding Horizons in Cancer Immunotherapy: IN8bio Welcomes The Ohio State University to the INB-100 Phase 1 Clinical Trial The pursuit of innovative cancer treatments takes another encouraging stride as IN8bio, a prominent biotechnology company focused on developing groundbreaking gamma-delta T cell therapies, has announced the expansion of its INB-100 Phase 1 clinical tria...
Product Service News

IN8bio Unveils Groundbreaking INB-600 A Game-Changer in T Cell Engagement for Oncology and Autoimmunity,

Published Fri, Jun 20 2025 10:34 AM UTC

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical firm based in New York, has announced the launch of its next-generation T cell-based T cell engager (TCE) platform, named INB-600. This pioneering technology aims to significantly improve treatment outcomes for patients with various forms of cancer and autoimmune diseases by addressing critical limitations found...
Clinical Study

IN8bio Achieves Milestone in Leukemia Treatment Pioneering Gamma-Delta T Cell Therapy Shows Promising Results in Clin...

Published Mon, Dec 30 2024 9:32 AM UTC

The landscape of leukemia treatment is undergoing significant evolution, particularly with the advent of innovative cell therapies. One company at the forefront of this paradigm shift is IN8bio, which has made remarkable strides with its groundbreaking INB-100, an allogeneic gamma-delta T cell therapy. Recent reports from the 2024 American Society of Hematology (ASH) Annual ...
Clinical Study

IN8bio’s INB-200 Shows Hopeful Potential for Glioblastoma With Durable Remissions Reported,

Published Mon, Nov 25 2024 12:01 PM UTC

IN8bio Announces Promising Outcomes in Phase 1 Trial of INB-200, Highlighted at Society for Neuro-Oncology Annual Meeting IN8bio, a burgeoning leader in the development of innovative cancer therapies, recently presented encouraging data from its Phase 1 clinical trial of INB-200 at the Society for Neuro-Oncology (SNO) Annual Meeting. The presentation, delivered as a plenary ...
Management Announcement

IN8bio's Resolute Focus on INB-100 Ignites Hope for Acute Myeloid Leukemia Patients amid Financial Hurdles,

Published Wed, Sep 4 2024 8:01 PM UTC

IN8bio s Strategic Prioritization: Focusing on INB-100 for Acute Myeloid Leukemia amidst Market Challenges
In a recent announcement, IN8bio Inc unveiled its clinical pipeline prioritization strategy, with an emphasis on INB-100, a potential breakthrough therapy for Acute Myeloid Leukemia (AML). As the company aims to address the pressing need for effective treatments in ...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 132.73
Price to Sales (Expected) -
Price to Book 1.11
PEG (TTM) -

Financial Strength Current
Quick Ratio 7.97
Working Capital Ratio 8.28
Leverage Ratio (MRQ) 0.18
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.49 $
Revenues (TTM) 0.01 $
Cash Flow (TTM) 0.45 $
Cash 0.92 $
Book Value 0.94 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 9,059
Net Income per Employee (TTM) -1,098,059
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.01

Profitability Ratios Current
Gross Margin (MRQ) 0 %
Operating Margin (MRQ) -3104.55 %
Net Margin (MRQ) -3104.55 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.